Abstract
Life expectancy is the most popular mortality indicator with demographers. Unless specified otherwise, it implicitly refers to the value at birth (age 0) of one of the functions derived through a period life table, a key tool of demographic and actuarial analysis. Demographers tend to favor life expectancy because it is a pure measure of the mortality conditions faced by a population, unaffected by that population’s age structure. Life expectancy also has an intuitive interpretation, conditional on the assumption that mortality conditions remain unchanged, as the expected age at death of an average newborn. If life table construction might be limited to an inner circle of demographers and actuaries, this interpretative ease gives life expectancy a much broader appeal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.